Media & Resources

New York, July 19, 2010— The International AIDS Vaccine Initiative (IAVI) is delighted by news that a clinical trial led by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) has provided the first evidence that a vaginal microbicide can provide women with protection from HIV infection. In the trial, named CAPRISA 004,…

IAVI Continues to Rank among Top One Percent of Charities Nationwide New York, July 14, 2010 — The International AIDS Vaccine Initiative (IAVI) has been awarded Charity Navigator’s four-star rating for the ninth year in a row—the organization’s highest ranking.  Charity Navigator, the nation’s largest independent charity evaluator, provides in-depth, objective ratings and analysis of the…

New York, July 6, 2010 — The International AIDS Vaccine Initiative (IAVI) announces the appointment of Margaret McGlynn, former President of Global Vaccines and Anti-infectives at Merck, to its board of directors. She joins a highly independent group of 16 advisors from 10 countries who meet three times a year to assess IAVI’s progress and shape…

New York, June 28, 2010 — The International AIDS Vaccine Initiative (IAVI) announced today that the Government of Japan pledged a US$10 million grant to support AIDS vaccine research and development over the next five years. The grant, which will be channeled through a newly established World Bank trust fund, is the first of its kind…

NEW YORK, May 13, 2010—In the 27 years since HIV was discovered, scientists have learned a great deal about the virus and how it causes AIDS. Making a vaccine to stop it, however, has proved a greater challenge than anyone could have imagined. Plain good news in this field has been a rarity. So it…

NEW YORK, NY and GAITHERSBURG, MD, April 22, 2010 — The International AIDS Vaccine Initiative (IAVI) and Lentigen today announced a collaboration to design a preventive AIDS vaccine based on Lentigen’s technology. The candidate AIDS vaccine will be devised to safely mimic biological aspects of HIV infection and tested first in pre-clinical studies as part…

NEW YORK, February 1, 2010—The International AIDS Vaccine Initiative (IAVI) is pleased to announce the appointment of David N. Cook as Executive Vice President and Chief Operating Officer. In this role, Cook will lead the senior management team, oversee IAVI’s operations and work closely with IAVI’s CEO Seth Berkley to drive the organization’s strategy for…

The International AIDS Vaccine Initiative (IAVI), Profectus BioSciences Inc. and Ichor Medical Systems announce today the start of a multi-center Phase I trial in Africa to evaluate the safety and immunogenicity of a preventive AIDS vaccine candidate. The trial is sponsored by IAVI and will be conducted in collaboration with Profectus, Ichor and three clinical…